Ultrafast Dynamic contract optical coherence tomography for high-throughput anti-cancer drug screening
$202,917P20FY2025GMNIH
University Of Oklahoma, Norman OK
Investigators
Linked publications & trials
Paper 39682305Paper 39544621Paper 39455542Paper 39346997Paper 39307410Paper 39223332Paper 39095532Paper 39065905Paper 39061760Paper 38946471Paper 38828467Paper 38732368Paper 38663008Paper 38633082Paper 38478444Paper 38460312Paper 38207109Paper 38182734Paper 38176434Paper 38045314Paper 38002458Paper 37982078Paper 37886456Paper 37833242Paper 37744460Paper 37609286Paper 37520860Paper 37205468Paper 37129853Paper 37083190Paper 37071747Paper 37015385Paper 36978712Paper 36738847Paper 36686152Paper 36670192Paper 36535032Paper 36522293Paper 36287799Paper 36119479Paper 36104215Paper 36048773Paper 35885455Paper 35868615Paper 35840643Paper 35820583Paper 35735499Paper 35510841Paper 35472844Paper 35213340Paper 35112157
Abstract
Improving the success rate of oncology drug development requires pre ... clinical models that better mimic in vivo tumor environments and advanced imaging tools capable of real-time monitoring of treatment responses. Tumor organoids represent a biologically relevant 3D cancer model, yet existing imaging platforms fall short in achieving both high temporal resolution and high throughput. To address this critical gap, we propose to develop an ultrafast Dynamic Contrast Optical Coherence Tomography (DyC-OCT) system empowered by artificial intelligence (Al) for label-free, high-throughput 4D imaging of tumor organoids.
View original record on NIH RePORTER →